Literature DB >> 21813751

Defining success for translational research organizations.

Robert Pozen1, Heather Kline.   

Abstract

Translational research organizations (TROs) seek to enhance the clinical impact of scientific discoveries and play a multifaceted role characterized by multidisciplinary collaboration, outreach initiatives, and the provision of shared resources and facilities. Given this complexity, TROs require a flexible framework for performance assessment that tracks their progress, incentivizes fruitful activities, and aligns individuals throughout the organization. We suggest a framework that assesses TRO performance along seven main dimensions-funding, talent, creation, validation, dissemination, external uptake, and collaboration-and we encourage individual organizations to develop additional metrics as needed.

Mesh:

Year:  2011        PMID: 21813751     DOI: 10.1126/scitranslmed.3002085

Source DB:  PubMed          Journal:  Sci Transl Med        ISSN: 1946-6234            Impact factor:   17.956


  12 in total

Review 1.  Critical appraisal of translational research models for suitability in performance assessment of cancer centers.

Authors:  Abinaya Rajan; Richard Sullivan; Suzanne Bakker; Wim H van Harten
Journal:  Oncologist       Date:  2012

2.  From an infrastructure to a service-based business model: 5 years of mobile clinical research at the University of Michigan.

Authors:  Margaret G McCammon; Christina M Conrad; Zachary T Klug; C Daniel Myers; Marie L Watkins; John W Wiley; Cynthia L Bower
Journal:  Clin Transl Sci       Date:  2013-01-14       Impact factor: 4.689

3.  Challenges facing translational research organizations in China: a qualitative multiple case study.

Authors:  Laixin Zhou; Ying Li; Hayden B Bosworth; John Ehiri; Changkun Luo
Journal:  J Transl Med       Date:  2013-10-13       Impact factor: 5.531

4.  Measuring the outcome of biomedical research: a systematic literature review.

Authors:  Frédérique Thonon; Rym Boulkedid; Tristan Delory; Sophie Rousseau; Mahasti Saghatchian; Wim van Harten; Claire O'Neill; Corinne Alberti
Journal:  PLoS One       Date:  2015-04-02       Impact factor: 3.240

Review 5.  Measuring research impact in Australia's medical research institutes: a scoping literature review of the objectives for and an assessment of the capabilities of research impact assessment frameworks.

Authors:  Simon Deeming; Andrew Searles; Penny Reeves; Michael Nilsson
Journal:  Health Res Policy Syst       Date:  2017-03-21

6.  Broadening measures of success: results of a behavioral health translational research training program.

Authors:  Julie A Baldwin; Heather J Williamson; Emery R Eaves; Bruce L Levin; Donna L Burton; Oliver T Massey
Journal:  Implement Sci       Date:  2017-07-24       Impact factor: 7.327

7.  Identifying potential indicators to measure the outcome of translational cancer research: a mixed methods approach.

Authors:  Frédérique Thonon; Rym Boulkedid; Maria Teixeira; Serge Gottot; Mahasti Saghatchian; Corinne Alberti
Journal:  Health Res Policy Syst       Date:  2015-12-03

Review 8.  Assessing excellence in translational cancer research: a consensus based framework.

Authors:  Abinaya Rajan; Carlos Caldas; Henri van Luenen; Mahasti Saghatchian; Wim H van Harten
Journal:  J Transl Med       Date:  2013-10-29       Impact factor: 5.531

9.  Markers of achievement for assessing and monitoring gender equity in translational research organisations: a rationale and study protocol.

Authors:  Pavel V Ovseiko; Laurel D Edmunds; Linda H Pololi; Trisha Greenhalgh; Vasiliki Kiparoglou; Lorna R Henderson; Catherine Williamson; Jonathan Grant; Graham M Lord; Keith M Channon; Robert I Lechler; Alastair M Buchan
Journal:  BMJ Open       Date:  2016-01-07       Impact factor: 2.692

Review 10.  Excellent translational research in oncology: A journey towards novel and more effective anti-cancer therapies.

Authors:  A Rajan; A Berns; U Ringborg; J Celis; B Ponder; C Caldas; D Livingston; R G Bristow; T T Hecht; T Tursz; H van Luenen; P Bono; T Helander; K Seamon; J F Smyth; D Louvard; A Eggermont; W H van Harten
Journal:  Mol Oncol       Date:  2015-12-23       Impact factor: 6.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.